SEARCH

SEARCH BY CITATION

References

  • 1
    Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update. Circulation. 2012; 125: e2220.
  • 2
    Beitnes JO, Lunde K, Brinchmann JE, et al. Stem cells for cardiac repair in acute myocardial infarction. Expert Rev Cardiovasc Ther. 2011; 9: 101525.
  • 3
    Choi YH, Kurtz A, Stamm C. Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther. 2011; 22: 317.
  • 4
    Malliaras K, Li T-S, Luthringer D, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells/clinical perspective. Circulation. 2012; 125: 10012.
  • 5
    Cui C-H, Uyama T, Miyado K, et al. Menstrual blood-derived cells confer human dystrophin expression in the murine model of duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Mol Biol Cell. 2007; 18: 158694.
  • 6
    Meng X, Ichim T, Zhong J, et al. Endometrial regenerative cells: a novel stem cell population. J Transl Med. 2007; 5: 57.
  • 7
    Patel AN, Silva F. Menstrual blood stromal cells: the potential for regenerative medicine. Regen Med. 2008; 3: 4434.
  • 8
    Dimitrov R, Timeva T, Kyurkchiev D, et al. Characterization of clonogenic stromal cells isolated from human endometrium. Reproduction. 2008; 135: 5518.
  • 9
    Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105: 938.
  • 10
    Pearl Jeremy I, Lee Andrew S, Leveson-Gower Dennis B, et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell. 2011; 8: 30917.
  • 11
    Ranganath Sudhir H, Levy O, Inamdar Maneesha S, et al. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012; 10: 24458.
  • 12
    Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006; 98: 107684.
  • 13
    Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res. 1982; 50: 10116.
  • 14
    Hu X, Yu SP, Fraser JL, et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008; 135: 799808.
  • 15
    Morooka M, Kubota K, Kadowaki H, et al. 11C-methionine PET of acute myocardial infarction. J Nucl Med. 2009; 50: 12837.
  • 16
    Timmers L, Lim SK, Arslan F, et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 2008; 1: 12937.
  • 17
    Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006; 20: 6619.
  • 18
    Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation/novelty and significance. Circ Res. 2010; 107: 91322.
  • 19
    Xaymardan M, Sun Z, Hatta K, et al. Uterine cells are recruited to the infarcted heart and improve cardiac outcomes in female rats. J Mol Cell Cardiol. 2012; 52: 126573.
  • 20
    Loffredo Francesco S, Steinhauser Matthew L, Gannon J, et al. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell. 2011; 8: 38998.
  • 21
    Dai B, Huang W, Xu M, et al. Reduced collagen deposition in infarcted myocardium facilitates induced pluripotent stem cell engraftment and angiomyogenesis for improvement of left ventricular function. J Am Coll Cardiol. 2011; 58: 211827.
  • 22
    Engel FB, Hsieh PCH, Lee RT, et al. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci USA. 2006; 103: 1554651.
  • 23
    Markel TA, Wang Y, Herrmann JL, et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol. 2008; 295: H230814.
  • 24
    Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004; 59: S216.
  • 25
    Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004; 15: 20513.
  • 26
    Cai W, Guzzo RM, Wei K, et al. A nodal-to-TGFβ cascade exerts biphasic control over cardiopoiesis. Circ Res. 2012; 111: 87681.
  • 27
    Gao D, Ning N, Niu X, et al. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am Heart J. 2012; 164: 71527. e1.
  • 28
    Zimmet H, Porapakkham P, Porapakkham P, et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail. 2012; 14: 91105.
  • 29
    Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2012; 2: CD006536.
  • 30
    Mirotsou M, Jayawardena TM, Schmeckpeper J, et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol. 2011; 50: 2809.
  • 31
    Hida N, Nishiyama N, Miyoshi S, et al. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells. 2008; 26: 1695704.
  • 32
    Dimmeler S, Zeiher AM. Cell therapy of acute myocardial infarction: open questions. Cardiology. 2009; 113: 15560.
  • 33
    Skalnikova H, Motlik J, Gadher SJ, et al. Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines. Proteomics. 2011; 11: 691708.
  • 34
    Hilfiker-Kleiner D, Hilfiker A, Fuchs M, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004; 95: 18795.
  • 35
    Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997; 88: 4357.
  • 36
    Matsuura K, Honda A, Nagai T, et al. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. J Clin Invest. 2009; 119: 220417.
  • 37
    Sharma V, Bell RM, Yellon DM. Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother. 2012; 13: 115375.
  • 38
    Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011; 378: 184757.
  • 39
    Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow–derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006; 355: 121021.
  • 40
    Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004; 109: 161522.
  • 41
    Behfar A, Yamada S, Crespo-Diaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010; 56: 72134.
  • 42
    Murphy M, Wang H, Patel A, et al. Allogeneic endometrial regenerative cells: an “Off the shelf solution” for critical limb ischemia? J Transl Med. 2008; 6: 45.
  • 43
    Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54: 227786.
  • 44
    Penn MS, Ellis S, Gandhi S, et al. Adventitial delivery of an allogeneic bone marrow–derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res. 2012; 110: 30411.
  • 45
    Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012; 308: 236979.
  • 46
    Zhong Z, Patel A, Ichim T, et al. Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med. 2009; 7: 15.